Background: Alzheimer's disease (AD) is the most common form of dementia. Neuroimaging methods have widened the horizons for AD diagnosis and therapy. The goals of this work are the synthesis of 2-(3-fluoropropyl)-6-methoxynaphthalene (5) Methods: Iron-catalysis cross coupling reaction, followed by fluorination and radiofluorination steps were carried out to obtain 5 and 18 F-Amylovis. Protein/Aß plaques binding, biodistribution, PET/CT Imaging and immunohistochemical studies were conducted in healthy/transgenic mice.
INTRODUCTION
The pathophysiological process of dementia associated with Alzheimer's disease (AD) begins years, if not decades, before cognitive impairment and clinical diagnosis [1, 2] . This process starts with the accumulation of senile plaques (SPs), mainly constituted by the amyloid β 1-42 (Aβ 1-42 ) peptide, which eventually leads to neuroinflammatory In our study, the synthesis of 2-(3-fluoropropyl) - 
EXPERIMENTAL

Organic Synthesis
General
All chemicals and reagents were obtained from commercial suppliers. Analytical TLC was performed on silica gel 60 F 254 (Merck, Germany), using benzene as a mobile phase. Silica gel (Silica 60, 230-400 mesh, Merck) was used to carry out chromatographic columns. IR spectra were recorded on a Beijing Rayleigh Analytical Instrument Corp. FTIR-WQF-510 spectrophotometer. NMR spectra were recorded on a Bruker Model AC 250F, JEOL ECLIPSE 400 and Bruker DPX-400 spectrometers. The chemical shifts assignment was based on standard NMR experiments ( 1 H, 1 H-COSY, HSQC, HMBC and 13 C NMR). The chemical shift values were expressed in ppm. Melting points were determined on an Electrothermal (model 9100, UK) equipment. Mass spectra were determined on a hybrid mass spectrometer with orthogonal geometry QTOF-2 (Micromass, UK) with electrospray ionization (ESI-MS).
Synthesis of Naphthalene Derivatives
6-bromo-2-naphthol (1)
6-bromo-2-naphthol was synthesized according to [18] . Yield: 95% (reported 96%) [18] , m.p: 123.3-127.7°C (reported 120-124°C) [18] . Rf: 0. 28 -7 , t); 117.13 (CH arom -2, C); 106.12 (C arom -6, c).
6-bromo-2-methoxynaphthalene (2)
6-bromo-2-methoxynaphthalene was synthesized according to [18] . Yield: 83% (reported 85%) [18] , m.p: 105-106.5°C (reported 103-105°C) [18] . Rf: 0. 63 
bromo(6-methoxy-2-naphthyl)magnesium (3)
A round-bottom flask (50 mL), equipped with a magnetic stirring bar and pressure equalizing funnel, was sealed with a rubber septum. Then, the air was evacuated and refilled four times with anhydrous argon. Magnesium turnings (61 mg, 2.5 mmol) and a speck of iodine were suspended in anhydrous THF (1.5 mL) and later, several drops of 2 (600 mg, 2.5 mmol) in THF (5 mL) were added. The reaction mixture was refluxed to initiate the reaction and when it became cloudy; the remaining of 2 solution was added dropwise and refluxed for 2 h additional.
General Procedure for Obtaining 3-(6-methoxy-2-naphthyl)propyl-4-methylbenzenesulfonate (4) by CrossCoupling Reactions
A round-bottom flask (50 mL), equipped with a magnetic stirring bar and pressure equalizing funnel, was sealed with a rubber septum, then evacuated and refilled four times with anhydrous argon. The flask was charged with 1,3-propanediol di-p-tosylate (DiTs, 711 mg, 1.87 mmol), catalyst (5 mol%, see Table 1 ) and co-ligand (Table 1) , and then anhydrous THF (11 mL) was added. This solution was stirred for 5 min and later, bromo(6-methoxy-2-naphthyl)magnesium (2.5 mmol, 6.25 mL anhydrous THF, 0.4 mol/L) was slowly added to the reaction mixture during 4 hours, at the selected temperature ( Table 1) . The reaction mixture was vigorously stirred at room temperature for an additional 24 h. During the reaction, a color change from red to green was observed. The reaction was quenched with NH 4 Cl saturated solution (6 mL 
2-(3-fluoropropyl)-6-methoxynaphthalene (5)
To a solution of 4 (370 mg, 1 mmol), in tert-amylic alcohol (4 mL), tetra-n-butylammonium fluoride (TBAF, 298 mg, 1 mmol) was added. The resulting mixture was stirred for 24 h, at 70 °C. Then, the solvent was removed under vacuum. The syrup was washed with distilled water (5 mL) and the organic compound was extracted with ethyl acetate (5 mL x 3). Standard extractive work-up followed by flash chromatography of the crude product was carried out (hexane: cyclohexane, 1:1) (198 mg, 0.91 mmol, 91%, purity 97%). Rf: 0. 6 
In silico Studies
Molecular Docking
The 3D-NMR structure of the Aβ 1-42 amyloid peptide was downloaded from the PDB (1IYT code) [19] . The structures of 5 and PIB were refined using Avogadro software [20] and converted into .pdbqt format with Autodock Tools, considering all ligand bonds as flexible. These compounds were blindly docked with Aβ 1-42 peptide using AutoDockVina [21] . The conformers with the lowest binding energy were calculated from 10 different conformations for each docking simulation between the peptide and the ligands, at 5 Å distance. For these simulations, all amino acids of the evaluated protein were considered in a rigid position. The folder with the data for calculation was compiled in a file, which contained the Aβ 1-42 configurations (.pdbqt) and the corresponding ligand configuration (.pdbqt). The selected values for the center of coordinates of the box were -1, 0, and 1 Å on the x, y, z-axis respectively, and the dimensions for each of the axes were 60, 60 and 70 Å. Thus, the ligand can move freely across the surface of the Aβ . The visualization and determination of the interaction zones between the amino acids and the tested compound were carried out using the molecular graphics program Pymol. The scoring function values were obtained from AutodockVina. Low root-mean-squaredeviation (RMSD) values were obtained in all assays. All calculations were performed on a cluster of 10 computers (30 CPU) using Linux as an operating system.
Molecular Dynamics Simulations
Molecular dynamics simulations were performed using GROMACS 4.6.5 [22] based on the docked conformation of 5 and amyloid peptide. An Amber 99SB force field was used for protein parameters [23] . Three Na + ions were added to neutralize the system and then solvated in a dodecahedron box of spc (simple point charge) water molecules. The PRODRG 2.5 [24] (available in the PRODRG website: http://davapc1.bioch.dundee.ac.uk/cgi-bin/prodrg) were used to generate all ligand parameters. To relieve any geometric strain and close intermolecular contacts, the ligand-peptide complex was subjected to previous steps of energy minimization and solvent and ions were equilibrated around amyloid peptide. Equilibration was conducted in two phases: NVT and NPT. In the NVT phase (constant number of particles, volume, and temperature), a weak constraint to the system was impose (10 kcal/mol) and was gradually heated from 0 to 300 K in 100 ps and then equilibrated for 100 ps at 300 K. In the NPT phase (constant number of particles, pressure, and temperature) the system was equilibrated for 100 ps at 300 K. A molecular dynamics simulations of 30 ns were performed with constant pressure (1 atm), temperature (300 K) and using periodic boundary conditions. 300 trajectory structures were obtained for subsequent analysis and the equilibration was monitored by examining the stability potential energy and the RMSD calculations between amyloid peptide backbone and each ligand. 30) ). The HPLC purification was performed using a C18 semi-preparative column and the mobile phase mentioned above at a flow rate of 4 mL/min. Chromatograms were registered using a UV (λ= 220 nm) and a gamma in-line detectors. The desired product was collected between 11 and 13 min and diluted with 50 mL of water for injection into a collection flask. This solution was again purified through a C18light-SPE cartridge, pre-activated with 1 mL of absolute ethanol followed by 10 mL of water for injection. The cartridge was washed with 10 mL of water for injection. The trapped product was eluted with 1 mL of absolute ethanol. Finally, formulation was done with 5.2 mL of 0.9% NaCl, 500 µL of Na 2 HPO 4 (0.1 mmol/L, pH 8.5) and 350 µL of a solution of Tween 80 (0.11 mmol/L in 0.9% NaCl). The final solution was transferred to a sterile vial through a 0.20 µm hydrophilic sterilizing filter and used in all assays.
Quality Control
Chemical and radiochemical purities were assessed by analytic RP-HPLC, with MeCN:H 2 O (75:25) as mobile phase, flow rate of 1 mL/min on a C18 column. Chromatograms were registered using UV (λ= 215 nm) and gamma detectors in series. The retention time of the precursor and the product were 11.0 and 8.4 min, respectively. Radiochemical identity was determined by comparing the retention time of the product with the nonradioactive reference standard. The radiochemical purity was determined integrating the area corresponding to the [
18 F]Amylovis´s peak in relation to the total radioactivity. Specific activity was calculated as the relation between the product activity at the end of synthesis and the amount of the unlabelled compound. Quality control of three different batches is summarized in Supplementary Material, Table 1S ).
Lipophilicity
The [
18 F]Amylovis partition coefficient was determined in n-octanol (2 mL) and phosphate buffer (2 mL, 0.1 mol/L, pH 7.4). The two phases were pre-saturated with each other. [ 18 F]Amylovis (100 µL) was added and the mixture was shaken by vortex for two minutes and centrifuged at 5 000 rpm for 5 min at 4°C. Subsequently, the two phases were separated and three samples (50 µL) of each phase were taken and their activity measured in a solid scintillation counter. Three replicates were performed and each one in triplicate. The partition coefficient was calculated using:
log P: log (counts in octanol/ counts in buffer).
In vitro Studies
[ 18 F]Amylovis Stability in the Final Formulation
Three samples of final formulation of [ 18 F]Amylovis were evaluated at different times (0, 1, 2, 3, 4, 5 and 6h) at room temperature. These samples were analyzed by analytical radio-HPLC using the conditions described in quality control.
Stability in Plasma
1 mL of human plasma was incubated with 100 µL of [
18 F]Amylovis at 37ºC for 2 hours. Plasma samples (100 µL) were taken at different incubation times (30, 60, 90 and 120 minutes). Plasma samples were extracted with 150 µL of absolute ethanol, at -15ºC, and mixed with a vortex to denaturalize the proteins. To precipitate proteins the mixtures were centrifuged (2 minutes, 5000 rpm at 4ºC). The supernatants were analyzed by radio-HPLC.
Protein Binding Assay
Molecular exclusion columns (Microspin TM G-50, GE Healthcare) were prepared by centrifugation (2 minutes, 3300 rpm at 4ºC). 1 mL of human plasma was incubated with 100 µL of [
18 F]Amylovis at 37ºC for 120 minutes. 50 µL of plasma samples were applied to the columns at different incubation times (30, 60 and 120 minutes) and incubated for 2 minutes. The columns were centrifuged (2 min, 3300 rpm at 4ºC) and eluates were collected. The radioactivity of columns (corresponding to free compound) and eluates (corresponding to binding compound) were measured by a gamma counter. A blank was carried out at 120 minutes of incubation, replacing plasma for 0.1 M phosphate buffer.
In vitro Binding Assays with Aβ Plaques
The binding assays were carried out by in vitro autoradiographic studies using post-mortem brain serial axial sections (10 µm) of homozygous 3xTg-AD mice (B6; 129Psen1tm1MpmTg(APPSwe, tauP301L)1Lfa/Mmjax, 9 months, female). Brain serial axial sections, over borosilicate glass, were pre-incubated for 10 min at room temperature in Tris-Mg buffer (tris-HCl 0.05 mol/L, pH 7; 45 mmol/L MgCl 2 and 0.002 % BSA), before testing. [26] from binding data, respectively, using GraphPad Prism software version 5.00 (San Diego, CA).
In vivo Studies
Biodistribution Study
Thirty healthy male Balb/C mice of 10-12 weeks and 28.5±2.0 g were divided into 6 groups of 5 
PET/CT Imaging Studies
Small animal PET/CT imaging studies were conducted in male C57BL/6 mice (nine animals, aged: 13 months) and in male transgenic APPSwe/PS1dE9 mice (nine animals, aged 12 months) [27] . Animals were anaesthetized with 4-5% isoflurane (maintenance 1-2 %) for all the studies they were involved. All applicable international and national guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were carried out in compliance with national regulation of Spain relating to conduct animal experimentation and the ethical standards of IBIS Ethical Committee. The study was also approved by CNA Scientific Committee. Anaesthetized animals were positioned in the imaging chamber of the microPET scanner (MicroPET Mosaic, Phillips, USA), which was kept at 38°C throughout the experiment. To these mice, 30-37 MBq (0.8 -1 mCi) of [
18 F]Amylovis was administered via lateral tail vein injection. The PET data from the 120 min dynamic scans were sorted into three-dimensional sinograms according to the following frame sequence: 10x2 min, 5x5 min and 5x15 min. CT-scans were performed in a NanoScan CT (Mediso, Hungary) at 45 kVp, 240 projections with 500 ms exposition time for anatomical reference. Decay corrected PET images of uniform 1 mm resolution were fused with CT images of uniform 0.2 mm resolution using PMOD 3.3 software (PMOD Technologies Ltd, Switzerland) by a rigid matching method. Then, CT image of the skull was fused in the same software with a predefined mouse brain template acquired in T2-weighted MRI included in PMOD [17] , to strip of the skull. The latter transformation was saved and applied to microPET images. This way, fused PET/CT images of 0.2 mm uniform resolution were obtained. Regions of interest were predefined in the template including: cerebellum, cortex, hypothalamus, thalamus, hippocampus, basal ganglia and brain stem. Radiopharmaceutical uptake was also evaluated in bladder, heart, liver, spleen, kidney, muscle and bone by means of PET images.
Immunohistochemical Study
Once the imaging study was concluded, deeply anaesthetized animals were perfused with a solution of 4% paraformaldehyde in 0.01 mol/L PBS pH=7.2. After death, their brains were removed, washed with saline, dried out, both hemispheres were separated and included in paraffin. Then, brains were sectioned in 4 µm thickness slices using a microtome. The sections were deparaffinized, hydrated in distilled water and treated with 70% formic acid for 30 min to retrieve the antigens. Afterwards, the slices were treated with 3% H 2 O 2 for 30 min, to remove residual peroxidase activity, and rinsed again with 0.01 mol/L PBS pH=7.2. Sections were then incubated overnight at 4°C with an anti-Aβ 1-42 monoclonal antibody (SIGMA, USA) diluted 1:1000. Then, slices were rinsed with 0.01 mol/L PBS pH=7.2 and incubated firstly with a ready to use secondary antibody (SIGMA, USA) for 30 min and secondly with a ready to use avidin-biotin-complex (SIGMA, USA) for 30 min at room temperature. For the staining, it was employed diaminobenzidine for 10 min. The slices were contrasted with Harris' haematoxylin and mounted in an aqueous medium. Slices from brains of healthy mice were taken as negative controls and received the same treatment showing no specific staining. The images of cortex, hippocampus, striatum, thalamus and cerebellum were visualized with the camera of the microscope Olympus BX51 (Japan).
Statistics
All numerical data are presented as mean value ± standard deviation. Grubbs' test was employed for outliers. Student's t-test was used to compare the uptake of [
18 F]Amylovis in brain regions of healthy and AD transgenic mice. A significance level of α=0.05 was considered for all tests.
RESULTS AND DISCUSSIONS
Chemistry
The synthesis of 2-(3-fluoropropyl)-6-methoxy naphthalene derivative [28] was carried out by means of several steps (Scheme 1).
The first step in this procedure is the bromination of 2-naphthol. This occurs according to the method reported by Koelsch [29] and Reddy [18] with a yield of over 95%. The O-alkylation reaction of 1 to afford 2-methoxy-6-bromonaphathalene (2) took place with (CH 3 ) 2 SO 4 as an alkylating agent, and Cs 2 CO 3 as a base [30] , in anhydrous acetone with an excellent yield.
The metal-catalyzed cross-coupling reactions (CCR) are carried out between an organometallic compound and an organic halide or pseudo halide. Further, it is catalyzed by transition metals, mainly nickel and palladium and recently by iron as a simple catalyst system (FeCl 3 or Fe(acac) 3 ) [31] [32] [33] [34] [35] , due to its low prices and ecological advantages [36] [37] [38] [39] . In this reaction sometimes, not only the desired product is obtained but also occurs the formation of impurities due to homo-coupling and β-elimination reactions [31, 32, [40] [41] [42] [43] [44] . For this reason, the experimental conditions should be properly controlled [37, 42, 45] . In this work, the CCR were assayed to obtain 3-(6-methoxy-2-naphthyl)propyl-4-methylbenzenesulfonate (4) using Fe(acac) 3 or (FeCl 3 ) 2 (TMEDA) 3 as catalysts and N,N,N′,N′-tetramethylethylenediamine (TMEDA) and/or hexamethylenetetramine (HMTA) as coligands [34] . The 1,3-propanediol-p-ditosylate (di-Ts), which is a bifunctional molecule, was employed in a molar ratio of 1:0.75 with respect to Grignard reagent (bromo(6-methoxy-2-naphthyl)magnesium, 3), to avoid the disubstituted product formation ( Table 1) .
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As it was expected in the absence of a catalyst, the desired product was not achieved even for different reaction temperatures assayed (three independent assays). In the cases that (FeCl 3 ) 2 (TMEDA) 3 was used as a catalyst and Grignard reagent was added at -20°C and 50°C (in Table 1 , entries 2 and 3), the reaction took place unsatisfactorily (low to moderate conversion). When TMEDA was used as a coligand (entry 4), the conversion grade from Grignard reagent to 4 increased up to 40%. Cahiez et al. described the use of Fe(acac) 3 and additives (such as TMEDA/HMTA) for CCR, with reaction yields around 70% [34] . Nonetheless, when Fe(acac) 3 and TMEDA/HMTA [34] were employed in CCR (entry 5), the yield was low. The use of TMEDA in a stoichiometric molar ratio or greater with respect to the Grignard reagent is recommended [46] to obtain better yields of product. Thus, similar experimental conditions were assayed (entry 6) and as expected, the conversion grade was higher.
The chemical structure of 4 was confirmed by 1 H-and 13 C-NMR spectra and mass spectrometry (see Supplementary Material, Fig. (1S) to (5S) [a] Reaction temperature reached after Grignard reagent´s addition. [b] Qualitatively determined by TLC.
[c] The Grignard reagent was added at -20 ºC (entries 1 and 2) and 50 ºC (entries 3 and 4).
two by-products were also obtained ( Table 1) : 2-methoxynaphthalene (6) and 6,6'-dimethyl-2, 2'-binaphthalene (7), which were identified by NMR (see Supplementary Material, Fig. (6S) to Fig. (7S) and Fig. (8S) to Fig. (9S) , respectively).
The nucleophilic fluorination of 4 (Scheme 1) to obtain 2-(3-fluoropropyl)-6-methoxynaphthalene (5) was carried out with tetrabutylammonium fluoride salt (TBAF) and tertamylic alcohol, according to the conditions described by Kim et al. [47] . The yield of the reaction was over 90%. The compound was purified by column chromatography and its purity was above 97%, determined by HPLC (see Supplementary Material, Fig. (10S) ). Fig. (12S) . Finally, in the TOF-ESI-MS the molecular ion peak at m/z 219.14 (around 75% abundance) was detected, confirming the structure of 5 (see Supplementary Material, Fig. (13S) ).
In silico Studies
Aβ 1-42 peptide and its conformational changes have been used as a molecular target for docking and molecular dynamics simulations to find compounds that can be employed as imaging probes for AD diagnosis or treatment [48] [49] [50] . It is known that there are three natural steric zippers due to the polymorphism of this peptide, which plays a key role in the β-cross structure formation. In the Aβ 1-42 peptide, the most studied steric zipper is located in the region from 16 to 21 a.a. (KLVFFA) [51] [52] [53] . In this work, a combination of docking and dynamic simulations along with binding free energy calculations (by Linear Interaction Energy, LIE) were done in order to understand the affinity and temporal stability of the complexes: 2-(3-fluoropropyl)-6-methoxynaphthalene (5)-Aβ peptide and PIB-Aβ peptide.
According to the rigid docking simulation, 5 interacts with amino acids 4-25 of Aβ peptide in all simulations, mainly with residues F4, D7, Y10, E11 Q15 K16 V18 F19 and F20. Under similar simulation conditions, PIB interacts with the amino acids 7-20 of Aβ peptide (in all simulations), mainly with residues D7 S8 E11 V12 Q15 K16 and F19 (see Supplementary Material, Fig. (14S) ).
A flexible docking approach was used, wherein all amino acids in this binding site were selected to have flexible side chains during simulation (Fig. 1) .
In the 99% of calculations for 5, the interaction zone included amino acids from 12 to 21, specifically with the residues Q15, K16, V18, F19, F20 (RMSD < 2 Å). In general, 5 binds to these residues via hydrophobic interactions and Van der Waals forces. The π-π interactions were located between the naphthyl ring of the ligand and the phenyl ring of the F19 and F20 residues, mainly with F19 (Fig. 1A) . Similar amino acids are involved in the interaction between PIB and peptide (RMSD < 2 Å) (Fig. 1B) . In this case, it was found an H-bond between the nitrogen atom of the benzothiazole ring of PIB and the hydrogen atom of amine group of K16, also a π-π hydrophobic interaction was located between the phenyl rings of PIB and F19. Fig. (1) . A: Flexible docking of 5 (at 5 Å distance): the π-π hydrophobic interactions were located between the naphthyl ring of 5 and the phenyl ring of the F19 and F20 residues. B: Flexible docking of PIB (at 5 Å distance): the H-bond was located between nitrogen atom of the benzothiazole ring of PIB and hydrogen atom of -NH 2 group of K16, and also a π-π hydrophobic interaction was located between the phenyl rings of PIB and F19.
The molecular dynamics (MD) calculations provide more detailed information about the stability of the ligand-peptide complex into biological environment, along the time. Two different assays were carried out: a) when the ligand 5 is near to Aβ 1-42 peptide (< 4 Å) (MD study I (see Supplementary Material, Fig. (15S) ; and b) when the ligands are transferred outside of the peptide interaction field (10 Å) (MD study II, Fig. 2) .
In MD studies (I and II), 5 interacts with the Aβ 1-42 peptide in the same region defined in dockings simulations. The calculated RMSD values were less to 2 Å during the assayed times which indicates that the interaction zone was practically unchanged. A similar result was obtained in MD study II for PIB-Aβ peptide complex (see Supplementary Material, Fig. (16S) ).
The calculation of the free energy (ΔG) was carried out using the LIE method for free energy. This method uses an average of the interactions between the ligand and its environment obtained by MD studies. The values of the mean square deviation errors, compared to the experimental energies, are less than ~ 1 kcal/mol [27, 54] . The ΔG values for 5-Aβ peptide complex indicated that at the beginning of the simulation there was no contact between the Aβ peptide and 5, therefore ΔG values were positives. After 5 ns of calculation, the ligand-peptide complex became more stable, with an average ΔG value of -5.31 kcal/mol. Similar behavior was obtained for PIB-Aβ peptide complex and the ΔG value was -4.12 kcal/mol.
Radiosynthesis
The radiosynthesis of compound 2-(3-[
18 F]fluoropropyl)-6-methoxynaphthalene ([ 18 F]Amylovis) was carried out in an automated synthesis platform. The labelled compound was purified by semi-preparative HPLC, and solid phase extraction (SPE) (Fig. 3) . [ 18 F]Amylovis was obtained with a ra- diochemical purity of 99.3% ± 0.3 (n=3). In all cases, the difference between retention times of [ 18 F]Amylovis and 5 was below 4%, as shown in Fig. (3) . Radionuclide identity and purity were confirmed by measuring its half-life and gamma spectrum, in all the batches. The global yield of synthesis was 24 ± 1% (decay corrected) and the specific activity was 351-616 GBq/µmol (see Supplementary Material, Table 1S and Fig. (17S) ).
The log P oct/PBS value of [
18 F]Amylovis was 2.46 ± 0.06 (two independent experiments, in triplicate), indicating that this radiopharmaceutical is moderately lipophilic (see Supplementary Material, Table 2S ), allowing to predict its ability to passively cross the BBB.
In vitro Stability Studies
The in vitro stability assay (radiochemical purity) of the final formulation of [
18 F]Amylovis showed that the compound did not significantly change after 6 h, at room temperature (see Supplementary Material, Table 3S ). In addition, the radiotracer was not degraded in fresh human plasma after 2 h incubation at 37ºC (see Supplementary Material, Table 4S ). Plasma protein binding (PPB) determination was carried out by gel filtration. The product showed a high PPB percentage, which was constant over time (see Supplementary Material, Table 5S Fig. (18S) and Fig. (19S) ).
Biodistribution Study
Biodistribution of [
18 F]Amylovis in healthy Balb/C male mice, at different times after i.v. the administration is summarized in Fig. (4) .
The high uptake values of [
18 F]Amylovis in kidneys and liver suggest that the urinary and hepatobiliary tracts were the main elimination pathways of this radiotracer; whilst the %ID/g (percentage injected dose per gram tissue) in kidneys was higher than values reported for other compounds with similarly estimated liposolubility [66] . The APPswe/PS1dE9 transgenic mouse model used in our study overexpresses the Swedish mutation of APP, together with PS1 deleted in exon 9 each driven by mouse PrP promoter. These mice develop the first plaques at four months of age, mainly in cortical areas and hippocampus [27] . Dynamic images of [ 18 F]Amylovis in brain tissue revealed a significant difference between the kinetic uptake in control healthy (C57BL/6, wild) and in transgenic mice. The uptake of Similarly, wild-type mice showed maximum activity at 2 min with a fast washout, in accordance with the results of biodistribution study; however, transgenic mice had slower uptake kinetics, with a peak at 23-25 min and a less pronounced washout. Such differences could be related to the specific binding of the tracer for the plaques in brain. Further studies should be conducted in order to have more evidence of this issue, as reported for other radiotracers by other authors [66] .
Considering that maximal cortex uptake of the [ 18 F]Amylovis was observed in dynamic images at about 25 min after administration, static PET images were performed at 30 min. Brendel M. et al. [2] found that the presence of amyloid plaques in cerebellar tissue of APPswe/PS1dE9 mice can significantly affect the standardized uptake value (SUV) relative to the cerebellum. Therefore, in the analysis of static images, the SUV was normalized at brain stem as proposed by other authors [2, 8] .
Comparative SUV of [ 18 F]Amylovis in some brain regions, regarding the brain stem, is summarized in Fig. (6) (n=3) . According to the immunohistochemical study, we found a significant number of amyloid plaques in the analyzed brain areas of APPSwe/PS1dE9 mice (Fig. 6-II) and among the cortex, hippocampus and thalamus presented the highest values, while cortex significantly differed from striatum and cerebellum (Duncan's test, F (4,100) = 4.98, p=0.001). Meanwhile, brain slices of control healthy mice showed an absence of β-amyloid deposits. A significantly augmented uptake of [ 18 F]Amylovis was observed in basal forebrain septum of transgenic animals in comparison to control healthy mice (p=0.0025) and a slightly incremented uptake of the radiopharmaceutical in cortex of transgenic mice was also found, despite it had no statistical significance. This fact could be influenced by the small size of the sample and also the age of transgenic mice (12 months ). An incremented number of amyloid plaques in APPSwe/PS1dE9 mice in regard to control healthy C57BL/6 mice was confirmed by the immunohistochemical assay.
CONCLUSION
2-(3-fluoropropyl)-6-methoxynaphthalene was successfully synthesized through an efficient procedure, that involves a cross-coupling reaction with a Grignard reagent and 1,3-dipropanediol-p-ditosylate as an electrophilic agent. The "cold" fluorinated compound 2-(3-fluoropropyl)-6-methoxynaphthalene was achieved with a high yield, using tetrabutylammonium fluoride salt in tert-amylic alcohol. In silico simulations indicated that 2-(3-fluoropropyl)-6-methoxynaphthalene forms a stable complex with the β-amyloid peptide by hydrophobic interactions, specifically with the amino acids Q15, K16, V18, F19, F20. This region was identified as a steric zipper implicated in the β-cross structure of Aβ plaques. The precursor, 3-(6-methoxy-2-naphthyl)propyl-4-methyl benzenesulfonate, was radiolabeled with [ 18 F]fluoride with a satisfactory yield (24.2 ± 1.4%), high radiochemical purity (> 99%) and specific activity (from 351 to 616 GBq/µmol). The log P oct/PBS value of [ 18 F]Amylovis point out to mild lipophilicity. Results of the in vitro binding assays in postmortem brain serial sections of 3xTg-AD mice showed an effective binding profile for the detection of Aβ plaques, which is in accordance with the outcomes of the in silico studies. In the biodistribution assay using healthy mice, [ 18 F]Amylovis shows good uptake into (7 %ID/g at 5 min post-injection) and fast clearance (0.11±0.03 %ID/g at 60 min) from the brain, which reveals that it passively cross the normal BBB. The kinetic uptake of [ 18 F]Amylovis in brain tissue of control healthy and transgenic mice is significantly different and the immunohistochemical study is in accordance with this results. All these results suggest that this compound could be a new potential PET probe for in vivo detection Aβ plaques in AD brains. Nevertheless, further studies should be accomplished to complete its preclinical assessment.
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